Cargando…

Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report

INTRODUCTION: Interleukin-1 receptor antagonist deficiency is a rare autoinflammatory disease involving neonatal onset of pustulosis, periostitis, and sterile osteomyelitis. The underlying genetic abnormality involves a recessive mutation in IL1RN, which encodes interleukin-1 receptor antagonist. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Ulusoy, Ezgi, Karaca, Neslihan Edeer, El-Shanti, Hatem, Kilicoglu, Erhan, Aksu, Guzide, Kutukculer, Necil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495801/
https://www.ncbi.nlm.nih.gov/pubmed/26100510
http://dx.doi.org/10.1186/s13256-015-0618-4
_version_ 1782380306860343296
author Ulusoy, Ezgi
Karaca, Neslihan Edeer
El-Shanti, Hatem
Kilicoglu, Erhan
Aksu, Guzide
Kutukculer, Necil
author_facet Ulusoy, Ezgi
Karaca, Neslihan Edeer
El-Shanti, Hatem
Kilicoglu, Erhan
Aksu, Guzide
Kutukculer, Necil
author_sort Ulusoy, Ezgi
collection PubMed
description INTRODUCTION: Interleukin-1 receptor antagonist deficiency is a rare autoinflammatory disease involving neonatal onset of pustulosis, periostitis, and sterile osteomyelitis. The underlying genetic abnormality involves a recessive mutation in IL1RN, which encodes interleukin-1 receptor antagonist. In this case report, we describe a case of a 12-year-old Turkish girl who initially was presented at 1 year of age, older than previously reported children with interleukin-1 receptor antagonist deficiency, and with a novel mutation, p.R26X, in ILR1N. CASE PRESENTATION: Our patient developed pustular cutaneous lesions at 1 year of age. At the age of 12 years, she was hospitalized for arthralgia of her knees, elbows, and ankles and arthritis of the left knee, with simultaneous pustular cutaneous lesions. She was admitted to the intensive care unit because of septicemia and respiratory insufficiency during follow-up. A skin biopsy of hyperpigmented lesions demonstrated neutrophil infiltration in the epidermis and subepidermal pustular dermatosis. Interleukin-1 receptor antagonist deficiency was suspected, and genetic analysis revealed a homozygous mutation (p.R26X) in IL1RN, which led to a diagnosis of interleukin-1 receptor antagonist deficiency. Treatment with canakinumab (recombinant human anti-human interleukin-1β monoclonal antibody) 150mg subcutaneously once every 6 weeks was initiated. Our patient did not experience further cutaneous lesions or arthritis. Her post-treatment inflammatory markers were normal; she gained weight; and she was able to walk independently. CONCLUSIONS: In this case report, we describe a patient with interleukin-1 receptor antagonist deficiency who responded excellently to canakinumab treatment. We believe more awareness is warranted for interleukin-1 receptor antagonist deficiency in children. It is possible that the mutation in our patient was a founder mutation that may lead to diagnosis of additional cases in Turkey.
format Online
Article
Text
id pubmed-4495801
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-44958012015-07-09 Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report Ulusoy, Ezgi Karaca, Neslihan Edeer El-Shanti, Hatem Kilicoglu, Erhan Aksu, Guzide Kutukculer, Necil J Med Case Rep Case Report INTRODUCTION: Interleukin-1 receptor antagonist deficiency is a rare autoinflammatory disease involving neonatal onset of pustulosis, periostitis, and sterile osteomyelitis. The underlying genetic abnormality involves a recessive mutation in IL1RN, which encodes interleukin-1 receptor antagonist. In this case report, we describe a case of a 12-year-old Turkish girl who initially was presented at 1 year of age, older than previously reported children with interleukin-1 receptor antagonist deficiency, and with a novel mutation, p.R26X, in ILR1N. CASE PRESENTATION: Our patient developed pustular cutaneous lesions at 1 year of age. At the age of 12 years, she was hospitalized for arthralgia of her knees, elbows, and ankles and arthritis of the left knee, with simultaneous pustular cutaneous lesions. She was admitted to the intensive care unit because of septicemia and respiratory insufficiency during follow-up. A skin biopsy of hyperpigmented lesions demonstrated neutrophil infiltration in the epidermis and subepidermal pustular dermatosis. Interleukin-1 receptor antagonist deficiency was suspected, and genetic analysis revealed a homozygous mutation (p.R26X) in IL1RN, which led to a diagnosis of interleukin-1 receptor antagonist deficiency. Treatment with canakinumab (recombinant human anti-human interleukin-1β monoclonal antibody) 150mg subcutaneously once every 6 weeks was initiated. Our patient did not experience further cutaneous lesions or arthritis. Her post-treatment inflammatory markers were normal; she gained weight; and she was able to walk independently. CONCLUSIONS: In this case report, we describe a patient with interleukin-1 receptor antagonist deficiency who responded excellently to canakinumab treatment. We believe more awareness is warranted for interleukin-1 receptor antagonist deficiency in children. It is possible that the mutation in our patient was a founder mutation that may lead to diagnosis of additional cases in Turkey. BioMed Central 2015-06-23 /pmc/articles/PMC4495801/ /pubmed/26100510 http://dx.doi.org/10.1186/s13256-015-0618-4 Text en © Ulusoy et al. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Ulusoy, Ezgi
Karaca, Neslihan Edeer
El-Shanti, Hatem
Kilicoglu, Erhan
Aksu, Guzide
Kutukculer, Necil
Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report
title Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report
title_full Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report
title_fullStr Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report
title_full_unstemmed Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report
title_short Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report
title_sort interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495801/
https://www.ncbi.nlm.nih.gov/pubmed/26100510
http://dx.doi.org/10.1186/s13256-015-0618-4
work_keys_str_mv AT ulusoyezgi interleukin1receptorantagonistdeficiencywithanovelmutationlateonsetandsuccessfultreatmentwithcanakinumabacasereport
AT karacaneslihanedeer interleukin1receptorantagonistdeficiencywithanovelmutationlateonsetandsuccessfultreatmentwithcanakinumabacasereport
AT elshantihatem interleukin1receptorantagonistdeficiencywithanovelmutationlateonsetandsuccessfultreatmentwithcanakinumabacasereport
AT kilicogluerhan interleukin1receptorantagonistdeficiencywithanovelmutationlateonsetandsuccessfultreatmentwithcanakinumabacasereport
AT aksuguzide interleukin1receptorantagonistdeficiencywithanovelmutationlateonsetandsuccessfultreatmentwithcanakinumabacasereport
AT kutukculernecil interleukin1receptorantagonistdeficiencywithanovelmutationlateonsetandsuccessfultreatmentwithcanakinumabacasereport